GlassScriptPhysician profile
Max P Benzaquen
NPI 1366426900
$105,180.42
in general payments reported to CMS, 2019-2025
82 companies · $7,677 in 2025
The $7,677 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $18K · 2021: $28K · 2022: $17K · 2023: $8,483 · 2024: $8,059 · 2025: $7,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Education: $560 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23,159.22 |
| Education | $560.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,219.44 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Allergan, INC. | $11,595.57 | 2019-2022 | |
| Lilly USA, LLC | $8,147.24 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Biohaven Pharmaceuticals, INC. | $7,185.04 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,002.06 | 2022 | |
| Jazz Pharmaceuticals INC. | $3,770.13 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,780.27 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Sk Life Science, INC. | $2,527.35 | 2020-2025 | |
| Greenwich Biosciences, INC. | $2,372.72 | 2019-2021 | |
| Lundbeck LLC | $2,234.79 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $2,218.29 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $2,170.94 | 2019-2024 | Qelbree |
| Ucb, INC. | $2,106.16 | 2019-2025 | Fintepla, Rystiggo, Zilbrysq |
| Biogen, INC. | $2,080.48 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Neurocrine Biosciences, INC. | $1,859.97 | 2019-2025 | Ingrezza, Ongentys |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,841.28 | 2019-2025 | Hizentra |
| Validus Pharmaceuticals LLC | $1,819.73 | 2019-2024 | Equetro |
| Emd Serono, INC. | $1,734.80 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $1,407.32 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $1,397.62 | 2019-2025 | Nuplazid, Daybue |
| Genentech USA, INC. | $1,279.45 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Otsuka America Pharmaceutical, INC. | $1,273.17 | 2022-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $1,212.20 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $1,170.17 | 2019-2025 | |
| Neurelis, INC. | $1,058.09 | 2020-2025 | Valtoco |
| Mdd US Operations, LLC | $962.78 | 2019-2024 | Apokyn, Apokyn, Gocovri |
| Eisai INC. | $954.38 | 2019-2025 | |
| Amgen INC. | $853.96 | 2019-2025 | Uplizna, Aimovig |
| Amneal Pharmaceuticals LLC | $852.19 | 2019-2025 | Rytary, Crexont, Ongentys |
| Upsher-Smith Laboratories LLC | $713.29 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $705.53 | 2024-2025 | Ponvory, Fanapt |
| Harmony Biosciences LLC | $629.10 | 2024-2025 | |
| Kyowa Kirin, INC. | $612.64 | 2020-2024 | Nourianz |
| Argenx US, INC. | $611.60 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $600.63 | 2019-2025 | Trintellix |
| Tanabe Pharma America, INC. | $573.28 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $513.15 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $508.26 | 2020-2022 | |
| Genzyme Corporation | $500.07 | 2019-2023 | |
| Impel Pharmaceuticals INC. | $442.48 | 2022-2023 | Trudhesa |
| Grifols USA, LLC | $369.58 | 2019-2025 | Gamunex-C |
| Avanir Pharmaceuticals, INC. | $323.21 | 2019-2022 | |
| Celgene Corporation | $305.21 | 2022-2025 | Zeposia |
| Sumitomo Pharma America, INC. | $294.99 | 2023-2024 | Aptiom |
| Axsome Therapeutics, INC. | $281.05 | 2023-2025 | Symbravo, Auvelity |
| E.R. Squibb & Sons, L.L.C. | $276.37 | 2020-2025 | Zeposia |
| Scilex Pharmaceuticals INC. | $234.81 | 2019 | |
| Ge Healthcare | $232.57 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $215.70 | 2023-2024 | Fycompa |
| Astrazeneca Pharmaceuticals LP | $215.29 | 2021-2022 | |
| Bausch Health US, LLC | $209.62 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $189.88 | 2019-2021 | |
| Banner Life Sciences, LLC | $122.50 | 2021 | |
| Acorda Therapeutics, INC | $121.77 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $116.59 | 2020 | |
| Azurity Pharmaceuticals, INC. | $91.81 | 2024-2025 | Horizant |
| Alnylam Pharmaceuticals INC. | $88.92 | 2020-2022 | |
| Tersera Therapeutics LLC | $81.30 | 2019 | |
| Janssen Biotech, INC. | $76.99 | 2025 | |
| Merck Sharp & Dohme LLC | $71.53 | 2021-2023 | Belsomra |
| Kedrion Biopharma, INC. | $68.07 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Avion Pharmaceuticals | $65.60 | 2022-2023 | Dhivy |
| Promius Pharma LLC | $64.66 | 2019 | |
| Xeris Pharmaceuticals, INC. | $62.62 | 2025 | Keveyis |
| Ipsen Biopharmaceuticals, INC | $51.54 | 2019 | |
| Tg Therapeutics, INC. | $40.92 | 2025 | |
| Merz Pharmaceuticals, LLC | $37.98 | 2025 | Xeomin |
| Assertio Therapeutics, INC. | $35.96 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.65 | 2024 | Caplyta |
| Sanofi-Aventis U.S. LLC | $34.71 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $32.93 | 2019 | |
| Alfasigma USA, INC. | $29.83 | 2022 | |
| Collegium Pharmaceutical, INC. | $27.98 | 2019-2021 | |
| Corium, LLC | $27.83 | 2023 | Adlarity |
| Currax Pharmaceuticals LLC | $26.86 | 2021 | |
| Vertical Pharmaceuticals, LLC | $25.71 | 2019-2020 | |
| Noven Therapeutics, LLC | $22.05 | 2024 | Xelstrym |
| Averitas Pharma INC. | $20.56 | 2023 | Qutenza |
| Endo Pharmaceuticals INC. | $13.84 | 2020 | |
| Zyla Life Sciences, INC. | $13.17 | 2020 | |
| Abbott Laboratories | $12.76 | 2022 | |
| Hospira, INC. | $11.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Benzaquen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.